Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Expert Opinion on Drug Safety|July 2, 2016
A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemiaMoussab Damlaj, Jeffrey H Lipton, Sarit E Assouline
Ebiomedicine|February 4, 2018
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline PathwayBenet Pera, Jan Krumsiek, Sarit E Assouline, et al.
Blood|March 23, 2012
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignanciesLaurie H Sehn, Sarit E Assouline, Douglas A Stewart, et al.
Leukemia & Lymphoma|October 16, 2012
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186David A Macdonald, Sarit E Assouline, Joseph Brandwein, et al.
Plos One|August 8, 2013
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytesMay Shawi, Tsz Wai Chu, Veronica Martinez-Marignac, et al.
British Journal of Haematology|April 26, 2017
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphomaConnie L Batlevi, Michael Crump, Charalambos Andreadis, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2025
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin LymphomaSarit E Assouline, Amitkumar Mehta, Walter Hanel, et al.
Current Medical Research and Opinion|October 8, 2024
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trialJudith Trotman, Pier Luigi Zinzani, Yuqin Song, et al.
Cancer|November 14, 2018
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemiaAdi J Klil-Drori, Hui Yin, Laurent Azoulay, et al.
Leukemia Research|September 1, 2023
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapyFatima M Khadadah, Sonia Cerquozzi, Harold J Olney, et al.
Pageof 3